[US-헬스케어] 07/02 Wall St. Recap
LLYBULL Eli Lilly (LLY) continues to demonstrate strong upward momentum, driven by its dominant position in the GLP-1 receptor agonist market. The recent surge is primarily attributed to positive clinical data regarding its next-generation obesity therapeutics, which reinforces investor confidence…